Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical and Translational Science|February 9, 2023
A mechanistic PK/PD model to enable dose selection of the potent anti-tryptase antibody (MTPS9579A) in patients with moderate-to-severe asthmaSharon M Rymut, Lindsay M Henderson, Victor Poon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 20, 2023
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)Yanke Yu, Michael E Rothenberg, Han Ting Ding, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 2, 2025
Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC-6988Rui Zhu, Ian Sorrell, Fang Ma, et al.
Pulmonary Pharmacology & Therapeutics|September 30, 2021
Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polypsRui Zhu, Ryan Owen, Justin Wilkins, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2020
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsPhilippe Gevaert, Theodore A Omachi, Jonathan Corren, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, et al.
Nucleic Acids Research|November 23, 2007
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledgeTina Hernandez-Boussard, Michelle Whirl-Carrillo, Joan M Hebert, et al.
Clinical and Translational Science|February 14, 2022
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteersRui Zhu, Hubert Chen, Joshua Galanter, et al.
Clinical and Translational Science|June 23, 2023
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteersFei Tang, Rebecca Kunder, Tom Chu, et al.
Pulmonary Pharmacology & Therapeutics|June 1, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammationHubert Chen, Rebecca Kunder, Yixuan Zou, et al.
Pageof 2